HighTower Advisors’s Codiak BioSciences, Inc. Common Stock CDAK Stock Holding History

HighTower Advisors’s Portfolio CDAK Stock Details CDAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-20,328	Closed	-$4K	–	3805
2023 Q1	$4K	Hold	20,328	–	–	﹤0.01%	3251
2022 Q4	$8K	Hold	20,328	–	–	﹤0.01%	3189
2022 Q3	$16K	Hold	20,328	–	–	﹤0.01%	2989
2022 Q2	$59K	Hold	20,328	–	–	﹤0.01%	2890
2022 Q1	$127K	Sell	20,328 -1,000	-5%	-$6.28K	﹤0.01%	2944
2021 Q4	$237K	Buy	+21,328	New	+$296K	﹤0.01%	2634

HighTower Advisors's CDAK Position: Q2 2023 in Review

HighTower Advisors sold out of Codiak BioSciences, Inc. Common Stock (CDAK) in Q2 2023, closing a stake of 20,328 shares — an estimated $4K sold.

HighTower Advisors first reported a position in CDAK in Q4 2021 and held it in 6 quarters. The position peaked at $237K in Q4 2021. 1 fund tracked by Wall St. Rank holds CDAK as of Q2 2023.

HighTower Advisors reported no remaining Codiak BioSciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
HighTower Advisors sold 20,328 Codiak BioSciences, Inc. Common Stock shares in Q2 2023, an estimated $4K.
HighTower Advisors first reported a position in Codiak BioSciences, Inc. Common Stock in Q4 2021 and held it in 6 quarters.
HighTower Advisors's Codiak BioSciences, Inc. Common Stock position peaked at $237K in Q4 2021.
1 fund tracked by Wall St. Rank held Codiak BioSciences, Inc. Common Stock as of Q2 2023.

Based on HighTower Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.